FL SB 1552
deadExperimental Treatments for Terminal Conditions and Life-threatening Rare Diseases
Florida · 2026 Regular Session · upper
Subscribe in a feed reader. The feed covers recorded actions from the last 30 days; Bill Commons may record an action after it happened at the legislature.
Quick answers
Did FL SB 1552 pass?
No. FL SB 1552 did not pass — it was defeated or died in the legislative process. Latest recorded action (2026-03-13): Died in Health Policy
What is FL SB 1552 about?
Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases; Citing this act as the “Promising Pathways Act"; authorizing licensed physicians to prescribe and eligible facilities to administer experimental treatments, if certain requirements are met; requiring the Department of Health to establish and maintain a patient registry for specified purposes; encouraging health insurers and health maintenance organizations to provide specified insurance coverage for experimental treatments; authorizing licensed physicians and eligible facilities to receive reimbursement for the prescription or administration of experimental treatments if certain requirements are met; requiring manufacturers of experimental treatments to provide for a specified temporary price concession set by the department, etc.
Who sponsors FL SB 1552?
Burgess is the primary sponsor of FL SB 1552.
Description
Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases; Citing this act as the “Promising Pathways Act"; authorizing licensed physicians to prescribe and eligible facilities to administer experimental treatments, if certain requirements are met; requiring the Department of Health to establish and maintain a patient registry for specified purposes; encouraging health insurers and health maintenance organizations to provide specified insurance coverage for experimental treatments; authorizing licensed physicians and eligible facilities to receive reimbursement for the prescription or administration of experimental treatments if certain requirements are met; requiring manufacturers of experimental treatments to provide for a specified temporary price concession set by the department, etc.
- Introduced
- 2026-01-22
- Latest action
- 2026-03-13 — Died in Health Policy
- Bill type
- bill
- Last updated
- —
Subjects
Sponsors
- Burgessprimary
Committees
Not provided by source.
Action timeline
Newest first
2026-03-13
Died in Health Policy
failure
2026-01-22
Introduced
introduction
2026-01-16
Referred to Health Policy; Appropriations Committee on Health and Human Services; Appropriations
referral-committee
2026-01-09
Filed
filing
Versions
- S 1552 FiledCompare
Documents
Votes
Not provided by source.
Related bills
No related bills recorded for this bill.
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:19:20.677932Z
Inspect retained evidence for changes recorded after evidence tracking began:
Session-wide evidence can include changes to other bills:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=FL&identifier=SB 1552. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.